Resecting Non–Contrast-Enhancing Tumor in Glioblastoma: Mitchel Berger, MD

​In patients with newly diagnosed glioblastoma, maximal extent of surgical resection of contrast-enhancing tumor has consistently been associated with benefits to survival. However, in a practice-changing study published recently in JAMA Oncology, a team of investigators under the leadership of Mitchel Berger, MD, found that extending resection to include non–contrast-enhancing tumor as well as contrast-enhancing tumor is associated with increased survival, regardless of tumor genetic subtype. I...
Continue reading

Maximal NCE Tumor Resection Impacts Glioblastoma Survival

​In patients with newly diagnosed glioblastoma, maximal extent of surgical resection of non–contrast enhanced (NCE) tumor as well as contrast-enhanced (CE) tumor is associated with increased survival regardless of tumor subtype, according to a study recently published in JAMA Oncology.Glioblastoma subtypes are known to impact disease outcome: while the 91% of patients with glioblastoma whose tumors display isocitrate dehydrogenase gene 1 or 2­­ (IDH) wild-type mutations have a median survival of...
Continue reading

Which Cervical Cancer Screening Is Most Cost-Effective?

A variety of cervical cancer screenings are available in the United States. However, the benefits, harms, and costs of all testing options are not known. In order to find out the cost-effectiveness of each type of cervical cancer test, researchers conducted a study analyzing 12 testing strategies.For this study, published in JAMA Internal Medicine, 451 women aged 21 to 65 years were enrolled. Each woman was asked her preference regarding 23 cervical cancer screening-associated health states. The...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.